CME Group price target raised to $250 from $230 at UBS

UBS raised the firm’s price target on CME Group to $250 from $230 and keeps a Buy rating on the shares. CME outperformed slightly following the Q3 results, as its fiscal 2023 expense guidance was reduced and October futures volume is tracking up 12% year-over-year on continued strength in rates and commodities, the analyst tells investors in a research note. The firm says the equities complex continues to be soft, but is positioned for upside if volatility returns.